Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...

Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 ...

Furthermore, these vaccine candidates were granted Fast Track designation by the US FDA. If successful, these assets have the potential for future milestone payments and royalties to Novavax.

Our fair value estimate is 8.2% lower than Novavax's analyst price target of US$16.43 How far off is Novavax, Inc. (NASDAQ:NVAX) from its intrinsic value? Using the most recent financial data, we'll ...